Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The report covers the month of July 2025, specifically detailing a share repurchase executed on July 29, 2025. The transaction was conducted through Merrill Lynch International under a non-discretionary agreement established on June 4, 2025.
Key Financial Metrics and Transaction Details
The filing details a specific buyback transaction rather than full-period financial results. Key metrics for the transaction on July 29, 2025, include:
- Shares Purchased: 490,615 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,385.00p; highest price paid was 1,405.00p.
- Volume-Weighted Average Price (VWAP): 1,398.63p.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON).
- Cumulative Buyback: Since the program began on June 4, 2025, GSK has purchased 18,146,960 ordinary shares.
Capital Structure and Treasury Holdings
Following the July 29 transaction, the company's share capital status is as follows:
- Treasury Shares Held: 236,281,343 ordinary shares.
- Shares in Issue (excluding Treasury): 4,079,104,067 ordinary shares.
- Total Voting Rights: 4,079,104,067.
- Treasury Share Voting Percentage: 5.79% of total voting rights.
Material Changes and Outlook
The filing does not report material changes to revenue, profit, or cash flow, as it is a disclosure of a capital transaction. The purchase is part of an existing buyback program. The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in GSK's 2024 Annual Report on Form 20-F and Q1 2025 results.
Important Facts for Investor Verification
- Verify the total number of shares in issue (4,079,104,067) when calculating ownership percentages or voting thresholds under FCA Disclosure Guidance and Transparency Rules.
- Confirm the cumulative volume of the buyback program (18,146,960 shares since June 4, 2025) to assess the pace of capital return.
- Note that the treasury share holding represents 5.79% of voting rights, which may impact dilution calculations for new issuances.
- Review the "Risk Factors" in the 2024 Form 20-F for context on uncertainties affecting future financial performance.